Entrada Therapeutics (TRDA) Other Working Capital Changes (2022 - 2026)

Entrada Therapeutics' Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 46.52% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$7.2 million, a 23.19% increase from a year earlier, with the FY2025 full-year figure at -$8.3 million, up 8.29% from the prior year.
• Other Working Capital Changes grew to -$1.2 million in Q1 2026 per TRDA's latest filing, from -$1.5 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $211.6 million in Q1 2023 and bottomed at -$222.5 million in Q2 2023.
• The 5-year median for Other Working Capital Changes is $2.5 million (2026), against an average of $1.9 million.
• Across the five-year window, Other Working Capital Changes jumped 141.76% in 2023 and sank 350.54% in 2024, its largest moves.
• Year by year, Other Working Capital Changes stood at -$2.0 million in 2022, then soared by 141.76% to $841000.0 in 2023, then sank by 350.54% to -$2.1 million in 2024, then jumped by 30.33% to -$1.5 million in 2025, then rose by 19.48% to -$1.2 million in 2026.
• Per Business Quant, the three latest TRDA Other Working Capital Changes figures stand at -$1.2 million (Q1 2026), -$1.5 million (Q4 2025), and -$2.3 million (Q3 2025).